PDE10A and schizophrenia: Based on a study of intracellular signaling pathways demonstrating the effect of PDE10A inhibitors on overall signaling in the therapeutic direction of schizophrenia [76] and several studies demonstrating that PDE10A inhibitors produce behavioral effects that predict antipsychotic activity, similar to D2 antagonists [75,77,78,80,81,82], this study suggests that intracellular signaling pathways affected by PDE10A inhibitors in schizophrenia should be considered compensatory pathways, rather than pathological mediators.